2012—2014年昭通市第一人民医院保肝药应用分析

摘要

OBJECTIVE:To evaluate and analyze the application of hepatoprotective drugs in the First People's Hospital of Zhaotong(hereinafter referred to as "our hospital") during 2012-2014,and to provide reference for the rational use of hepatoprotective drugs in clinical practice.METHODS: The application data of hepatoprotective drugs in our hospital during 2012-2014 were statistically analyzed in terms of defined daily dose system( DDDs),daily drug cost ( DDC) and the ranking ratio.RESULTS:The consumption sum of hepatoprotective drugs increased year by year,the constitutional ratio of hepatoprotective essential drugs versus hepatoprotective drugs in consumption sum was over 50%.DDDs of Dangfeiliganning capsule and polyene phosphatidyl choline injection were higher than other drugs.DDC of hepatocyte growth-promoting factors injection and L-ornithine-L-aspartate for injection were in high levels.The ranking ratio of Dangfeiliganning capsule and Glucurolacton tablets were relatively high,but as for L-ornithine-L-aspartate for injection and hepatocyte growth-promoting factors injection,it was relatively low.CONCLUSIONS: The application of hepatoprotective drugs in our hospital are basically rational.%目的:分析评价昭通市第一人民医院(以下简称"我院")2012—2014年保肝药的应用情况,为合理应用该类药提供参考.方法:统计分析2012—2014年我院保肝药的销售金额、用药频度( defined daily dose system,DDDs)、限定日费用( daily drug cost,DDC)及排序比.结果:保肝药的销售金额逐年增加,保肝基本药物占保肝药销售金额比例>50%;当飞利肝宁胶囊、多烯磷脂酰胆碱注射液的DDDs较高;促肝细胞生长素注射液和注射用门冬氨酸鸟氨酸的DDC较高;当飞利肝宁胶囊、葡醛内酯片排序比较大,注射用门冬氨酸鸟氨酸、促肝细胞生长素注射液的排序比相对较小.结论:我院保肝药的应用基本合理.